Biomedical research institute
     
    You are here: Home / Departments / Infection, Immunity and Inflammation / Team E. Donnadieu

    Team: Cancer and Immune Response

    •  

    Team leader

     

     

    The team in brief… The objective of our team is to address questions related to the fields of cancer immunology and cancer immunotherapy. We aim at characterizing negative and positive regulators of anti-tumoral immune effector cells to improve current cancer treatments.

     

    Objectives

    Cancer immunotherapy has benefited from the development of approaches that target T cells. In particular, immune checkpoint inhibitors and adoptive T-cell therapies including chimeric antigen receptor (CAR) T cells are starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments.
    Over the last years, we have improved our understanding of key negative and positive regulations of anti-tumoral immune cells. We have also investigated how a successful immune response can be induced to lead to tumor regression and demonstrated that T cells and activated tumor-associated macrophages can work cooperatively in regressing tumors.
    Our objective is to propose new strategies aiming at increasing the efficacy of current cancer treatments. We take advantage of tools and expertise developed by the team including a preclinical model of tumor slices (link towards tissue slice page).

    Our project is focused on three main aspects:
    -    Improving the migration and function of CAR T cells in solid tumors (link towards ED page)
    -    Deciphering the cooperative action of T cells and macrophages against the tumor
    -    Investigating the role of the epigenetic factor RINF in the regulation of immune cell functions and in the control of solid tumors (link towards FP page)

     

     

    Main publications

     

    • Guerin, M. V., V. Finisguerra, B. J. Van den Eynde, N. Bercovici, and A. Trautmann. (2020). Preclinical murine tumor models: a structural and functional perspective. eLife 9. Jan 28;9. (http://www.ncbi.nlm.nih.gov/pubmed/31990272)
    • Guerin MV, Regnier F, Feuillet V, Vimeux L, Weiss JM, Guilbert T, Thoreau M, Renault G, Finisguerra V, Donnadieu E, Trautmann A*, Bercovici N*.(2019). TGFβ blocks STING-induced IFNα/β release and tumor rejection in spontaneous mammary tumors. Nature Communications. 10:4131. *Equal contribution. (http://www.ncbi.nlm.nih.gov/pubmed/31511510)
    • Daher C*, Vimeux L*, Stovea R, Peranzoni E, Bismuth G, Donnadieu E, Bercovici N, Trautmann A, Feuillet V. (2019). Blockade of β-adrenergic receptor signaling improves cancer vaccine efficacy through its effect on naive CD8+ T-cell priming. Cancer Immunology Research. 7:1849-1863. *Equal contribution. (http://www.ncbi.nlm.nih.gov/pubmed/31527069)
    • Bercovici N, Guerin MV, Trautmann A, Donnadieu E. (2019). The Remarkable Plasticity of Macrophages: A Chance to Fight Cancer. Frontiers in immunology  10:1563. (http://www.ncbi.nlm.nih.gov/pubmed/31354719)
    • Peranzoni E, Lemoine J, Vimeux L, Feuillet V, Barrin S, Kantari-Mimoun C, Bercovici N, Guerin M, Biton J, Ouakrim H, Regnier F, Lupo A, Alifano M, Damotte D, Donnadieu E (2018) Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proceedings of the National Academy of Sciences of the United States of America 115 (17):E4041-E4050. (http://www.ncbi.nlm.nih.gov/pubmed/29632196)

     

     

    Team’s news

     

    • The team has been recognized and funded as «Equipe de la Ligue Nationale contre le Cancer» (2020).

     

     

     


    • The team is a member of the SIRIC (a cancer research network) CARPEM (http://carpem.fr/), a program which gathers scientists and clinicians from several centers including Cochin and HEGP hospitals.



    •  The team has participated in a European project to develop innovative cancer therapy based on CAR T cells (2016-2019) (http://carat-horizon2020.eu/carat-network/partners-in-depth/inserm).




    • Emmanuel Donnadieu was interviewed on the Radio Suisse Romande (April 2018) (https://pages.rts.ch/la-1ere/programmes/cqfd/9445717-cancer-ameliorer-limmunotherapie-en-eliminant-les-macrophages-tumoraux-11-04-2018.html?mediaShare=1)

     

     

    Departments
    Departement Teams